Pharmacological evaluation of the novel thromboxane modulator BM-567 (II/II). Effects of BM-567 on osteogenic sarcoma-cell-induced platelet aggregation

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 68, Issue 1, 2003, Pages 55-59

  De Leval, X ^a   Benoit, V ^a   Delarge, J ^a   Julemont F ^a   Masereel, B ^b   Pirotte, B ^a   Merville, M P ^a   David, J L ^a   Dogne J M ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF NAMUR   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BM 567; N PENTYL N' [(2 CYCLOHEXYLAMINO 5 NITROBENZENE)SULFONYL]UREA; THROMBOXANE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CELL STIMULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FATTY ACID SYNTHESIS; HUMAN; HUMAN CELL; IC 50; METASTASIS; OSTEOSARCOMA CELL; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; TUMOR GROWTH;

BLOOD PLATELETS; BONE NEOPLASMS; CELL LINE, TUMOR; ENZYME INHIBITORS; HUMANS; OSTEOSARCOMA; PLATELET AGGREGATION INHIBITORS; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; SULFONYLUREA COMPOUNDS; THROMBOXANE-A SYNTHASE;

ANIMALIA;

EID: 12244261894     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(02)00235-1     Document Type: Article

References (22)

1. S. Karpatkin, E. Pearlstein, Role of platelets in tumor cell metastases, Ann. Intern. Med. 95 (1981) 636-641.
2. G.J. Gasic, T.B. Gasic, N. Galanti, T. Johnson, S. Murphy, Platelet-tumor-cell interactions in mice, The role of platelets in the spread of malignant disease, Int. J. Cancer 11 (1973) 704-718.
3. K.V. Honn, D.G. Tang, Y.Q. Chen, Platelets and cancer metastasis: more than an epiphenomenon, Semin. Thromb. Hemost. 18 (1992) 392-415.
4. G.J. Gasic, T.B. Gasic, Removal of sialic acid from the cell coat in tumor cells and vascular endothelium and its effects on metastasis, Proc. Natl. Acad. Sci. USA 48 (1962) 1172-1177.
5. G.J. Gasic, T.B. Gasic, C.C. Stewart, Antimetastatic effects associated with platelet reduction, Proc. Natl. Acad. Sci. USA 61 (1968) 46-52.
6. E. Pearlstein, C. Ambrogio, G. Gasic, S. Karpatkin, Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic routine tumor with a specific thrombin inhibitor: dansylarginine N-(3-ethyl-1, 5-pentanediyl)amide, Prog. Clin. Biol. Res. 89 (1982) 479-502.
7. A. Tohgo, N.G. Tanaka, H, Ogawa, Platelet-aggregating activities of metastasizing tumor cells. III. Platelet aggregation as resulting from thrombin generation by tumor cells, Invasion Metastasis 5 (1985) 96-105.
8. K.E. Ugen, M. Mahalingam, P.A, Klein, K.J. Kao, Inhibition of tumor cell-induced platelet aggregation and experimental tumor metastasis by the synthetic Gly-Arg-Gly-Asp-Ser peptide, J. Natl. Cancer Inst. 80 (1988) 1461-1466.
9. E. Bastida, A. Ordinas, S.L. Giardina, G.A. Jamieson, Differentiation of platelet-aggregating effects of human tumor cell lines based on inhibition studies with apyrase, hirudin, and phospholipase, Cancer Res. 42 (1982) 4348-4352.
10. Y. Katagiri, Y. Hayashi, I. Baba, H. Suzuki, K. Tanoue, H. Yamazaki, Characterization of platelet aggregation induced by the human melanoma cell line HMV-I: roles of heparin, plasma adhesive proteins, and tumor cell membrane proteins, Cancer Res. 51 (1991) 1286-1293.
11. E. Pearlstein, P.L. Salk, G. Yogeeswaran, S. Karpatkin, Correlation between spontaneous metastatic potential, platelet-aggregating activity of cell surface extracts, and cell surface sialylation in 10 metastatic-variant derivatives of a rat renal sarcoma cell line, Proc. Natl. Acad. Sci. USA 77 (1980) 4336-4339.
12. J.M. Dogné, X. de Leval, J. Delarge, J.L. David, B. Masereel, New trends in thromboxane and prostacyclin modulators, Curr. Med. Chem. 7 (2000) 609-628.
13. K.V. Honn, Inhibition of tumor cell metastasis by modulation of the vascular prostacyclin/thromboxane A2 system, Clin. Exp. Metastasis 1 (1983) 103-114.
14. 2, Fed. Proc. 46 (1987) 133-138.
15. D. Nie, M. Lamberti, A. Zacharek, L. Li, K. Szekeres, K. Tang, Y. Chen, K.V. Honn, Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis, Biochem. Biophys. Res. Commun. 267 (2000) 245-251.
16. I. Yokoyama, S. Hayashi, T. Kobayashi, M. Negita, M. Yasutomi, K. Uchida, H. Takagi, Prevention of experimental hepatic metastasis with thromboxane synthase inhibitor, Res. Exp. Med. 195 (1995) 209-215.
17. 2 inhibition on osteogenic sarcoma cell-induced platelet aggregation, Cancer Res. 46 (1986) 5061-5063.
18. C. Voland, C.M. Serre, P. Delmas, P. Clezardin, Platelet-osteosarcoma cell interaction is mediated through a specific fibrinogen-binding sequence located within the N-terminal domain of thrombospondin 1, J. Bone Miner. Res. 15 (2000) 361-368.
19. P. Clezardin, J. Drouin, M.C. Morel-Kopp, M. Hanss, B. Kehrel, C.M. Serre, C. Kaplan, P.D. Delmas, Role of platelet membrane glycoproteins Ib/IX and IIb/IIIa, and of platelet alpha-granule proteins in platelet aggregation induced by human osteosarcoma cells, Cancer Res. 53 (1993) 4695-4700.
20. K.V. Honn, D.G. Menter, J.M. Onoda, J.D. Taylor, B.F. Sloane, Role of prostacyclin as a natural deterrent to hematogenous tumor metastasis, Symp. Fundam. Cancer Res. 36 (1983) 361-388.
21. B. Nieswandt, M. Hafner, B. Echtenacher, D.N. Mannel, Lysis of tumor cells by natural killer cells in mice is impeded by platelets, Cancer Res. 59 (1999) 1295-1300.
22. A. Tohgo, N.G. Tanaka, Y. Osada, Inhibitory effects of DN-9693 on platelet-enhanced tumor cell attachment to cultured endothelium, Invasion Metastasis 10 (1990) 1-17.